Chorokbaem Healthcare Co Ltd (118000) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Chorokbaem Healthcare Co Ltd KRW 511, price KRW 1,273, upside -59.8%, quality 37 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Chorokbaem Healthcare Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 223.00 KRW – 2,268 KRW · fair‑value band 369.82 KRW – 797.65 KRW · the 1,273 KRW price screens above the 511.24 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Chorokbaem Healthcare Co in your weekly email
Every Wednesday you see whether Chorokbaem Healthcare Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
METACARE CO., Ltd. distributes pharmaceuticals and medical devices in South Korea. The company sells orthopedic medical devices and consumables; and provides pharmaceutical integration and professional logistics services. It is involved in investment advisory. The company was formerly known as SMEDI Co., Ltd. and changed its name to METACARE CO., Ltd.
Show more
METACARE CO., Ltd. distributes pharmaceuticals and medical devices in South Korea. The company sells orthopedic medical devices and consumables; and provides pharmaceutical integration and professional logistics services. It is involved in investment advisory. The company was formerly known as SMEDI Co., Ltd. and changed its name to METACARE CO., Ltd. in August 2024. METACARE CO., Ltd. was founded in 2009 and is headquartered in Hwaseong-si, South Korea.
Stock analysis
Chorokbaem Healthcare Co Ltd (118000) currently trades at 1,273 KRW, while our model-based Fair Value estimate is 511.24 KRW, implying the stock looks roughly 149.0% overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of 4,658 KRW per share, and 3 of the 11 models we run sit above the 1,273 KRW price.
Bear case: the Earnings-Based group reads lowest at 285.70 KRW, and 8 of the 11 models stay below the price. Evidence for this calculation is low.
Scenario range: 369.82 KRW (bear) to 797.65 KRW (bull), the price of 1,273 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Chorokbaem Healthcare Co Ltd reported revenue of 32.8B KRW in FY2025 versus 18.6B KRW in FY2021, a compound +15.2%/yr. Reported net income was 498M KRW in FY2025, compounding −49.6%/yr from FY2021.
Key figures
Market cap 21.9B KRW (≈ $16.1M) · P/S ratio 0.61 · Net margin 1.5% · Return on equity 0.4% · Return on assets (EBIT) 0.2% · Operating margin 5.7% · Revenue (TTM) 36.9B KRW · Revenue growth (YoY) +68.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).
What moves the price
The share trades about 43% below its 52-week high and 471% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 1% fair-value upside, at −60%, 118000 screens richer than that median.
Fair Value models
Bear 369.82 KRWFair Value 511.24 KRWBull 797.65 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.29/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+62.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.1%
Start year 2020 (pandemic). Over 10 years: +11.1% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−27.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year−27.7%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−8% → 4%
⚠ Revenue per share shrinking 2.4%/yr over ~6Y (margin trend unclear) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Compare Chorokbaem Healthcare Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 74 stocks
Beats the industry median on 2/9 measures
Overall it trails its industry peers.
Valuation
Quality Score37 · Bottom 25%
Fair Value upside−60% · Bottom 25%
Profitability
Return on equity (TTM)0% · Bottom 25%
Return on assets0% · Bottom 25%
Net margin (TTM)3% · Bottom 25%
Operating margin (TTM)6% · Bottom 25%
Growth and dividend
Revenue growth69% · Top 25%
Balance sheet
Debt / equity0.19× · Above median
Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper
EV/EBITDA4.5× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 20
FUTURE (revenue growth)100· sector 29
PAST (return on equity)2· sector 48
HEALTH (low debt)90· sector 94
DIVIDEND (yield)0· sector 42
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Chorokbaem Healthcare Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/118000
Frequently asked questions
Is Chorokbaem Healthcare Co Ltd (118000) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 511.24 KRW versus a price of 1,273 KRW, about −60% upside (overvalued).
What is the fair value of 118000?
Our model-based fair value for Chorokbaem Healthcare Co Ltd is 511.24 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 1,273 KRW.
What is the quality score of 118000?
Chorokbaem Healthcare Co Ltd has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Chorokbaem Healthcare Co Ltd (118000)?
Our model-based price target is the fair value of 511.24 KRW (as of Sep 24, 2026) from 12 valuation models. Cautious scenario 369.82 KRW, optimistic scenario 797.65 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Chorokbaem Healthcare Co Ltd stock forecast for 2026?
Our models put fair value at 511.24 KRW, about −60% upside versus a price of 1,273 KRW (overvalued). Cautious scenario 369.82 KRW, optimistic scenario 797.65 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Chorokbaem Healthcare Co Ltd (118000)?
Chorokbaem Healthcare Co Ltd reported trailing-twelve-month revenue of about 36.9B KRW (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Chorokbaem Healthcare Co Ltd (118000)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Chorokbaem Healthcare Co Ltd it is 511.24 KRW per share (as of Sep 24, 2026), against a price of 1,273 KRW. It is the blended result of 12 valuation models (cash flow, earnings, asset, dividend).
Is Chorokbaem Healthcare Co Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 118000 trades above its calculated fair value: price 1,273 KRW, fair value 511.24 KRW, a gap of about −60% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 118000?
No. The price is what the market pays today (1,273 KRW); the fair value is what the company's own numbers justify (511.24 KRW). For Chorokbaem Healthcare Co Ltd the two are 761.76 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Chorokbaem Healthcare Co Ltd worth?
The market values Chorokbaem Healthcare Co Ltd at about 21.9B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 1,273 KRW; our models calculate a fair value of 511.24 KRW per share.
What do the bullish and bearish scenarios say about 118000?
Our models span a range for Chorokbaem Healthcare Co Ltd: cautious scenario 369.82 KRW, base 511.24 KRW, optimistic 797.65 KRW per share (as of Sep 24, 2026, price 1,273 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Chorokbaem Healthcare Co Ltd (118000)?
Balance-sheet figures for Chorokbaem Healthcare Co Ltd (as of Sep 24, 2026): return on equity 0.4%, debt of 0.19 per unit of equity. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is 118000 from its 52-week high?
Chorokbaem Healthcare Co Ltd trades at 1,273 KRW, about 43% below its 52-week high of 2,220 KRW and 471% above the low of 223.00 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 511.24 KRW is for.
Which stocks are comparable to Chorokbaem Healthcare Co Ltd?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Chorokbaem Healthcare Co Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 1,273 KRW, calculated fair value 511.24 KRW (−60%), Quality Score 37/100, from 12 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 118000 calculated?
We run Chorokbaem Healthcare Co Ltd through 12 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 511.24 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Chorokbaem Healthcare Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Chorokbaem Healthcare Co Ltd (118000)?
The closing price on Sep 23, 2026 was 1,273 KRW. Our model-based fair value is 511.24 KRW, about −60% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Chorokbaem Healthcare Co Ltd right now?
The price sits above even our optimistic bull case (797.65 KRW). The favourable scenario is already priced in. Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (369.82 KRW to 797.65 KRW) leaves room in how you read the outcome.
Key figures of Chorokbaem Healthcare Co Ltd
How large is the market capitalisation of Chorokbaem Healthcare Co Ltd (118000)?
The market capitalisation of Chorokbaem Healthcare Co Ltd is 21.9B KRW (≈ $16.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Chorokbaem Healthcare Co Ltd (118000)?
The price-to-sales ratio of Chorokbaem Healthcare Co Ltd is 0.61 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Chorokbaem Healthcare Co Ltd (118000)?
The net margin of Chorokbaem Healthcare Co Ltd is 1.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Chorokbaem Healthcare Co Ltd (118000)?
The return on equity (ROE) of Chorokbaem Healthcare Co Ltd is 0.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Chorokbaem Healthcare Co Ltd (118000)?
On an EBIT basis the return on assets of Chorokbaem Healthcare Co Ltd is 0.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Chorokbaem Healthcare Co Ltd (118000)?
The operating margin of Chorokbaem Healthcare Co Ltd is 5.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Chorokbaem Healthcare Co Ltd (118000)?
Revenue at Chorokbaem Healthcare Co Ltd is growing +68.8% versus a year earlier (3y avg +19.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Chorokbaem Healthcare Co Ltd (118000)?
Earnings per share at Chorokbaem Healthcare Co Ltd are growing +150% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Chorokbaem Healthcare Co Ltd (118000) generate?
The free cash flow of Chorokbaem Healthcare Co Ltd is −4.9B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Chorokbaem Healthcare Co Ltd (118000) carry?
The net debt of Chorokbaem Healthcare Co Ltd is 57.6B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Chorokbaem Healthcare Co Ltd in the live analysis
One click puts Chorokbaem Healthcare Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
